GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cartesian Therapeutics Inc (NAS:RNAC) » Definitions » Cyclically Adjusted PB Ratio

Cartesian Therapeutics (Cartesian Therapeutics) Cyclically Adjusted PB Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cartesian Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cartesian Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cartesian Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cartesian Therapeutics Cyclically Adjusted PB Ratio Chart

Cartesian Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cartesian Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cartesian Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Cartesian Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cartesian Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cartesian Therapeutics's Cyclically Adjusted PB Ratio falls into.



Cartesian Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cartesian Therapeutics's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Cartesian Therapeutics's adjusted Book Value per Share data for the fiscal year that ended in Dec23 was:

Adj_Book=Book Value per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=-81.552/129.4194*129.4194
=-81.552

Current CPI (Dec23) = 129.4194.

Cartesian Therapeutics Annual Data

Book Value per Share CPI Adj_Book
201412 -204.557 99.070 -267.222
201512 -206.621 99.792 -267.964
201612 89.416 101.863 113.606
201712 69.570 104.011 86.565
201812 -7.233 105.998 -8.831
201912 2.918 108.420 3.483
202012 -4.998 109.897 -5.886
202112 5.465 117.630 6.013
202212 18.393 125.222 19.010
202312 -81.552 129.419 -81.552

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cartesian Therapeutics  (NAS:RNAC) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cartesian Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cartesian Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cartesian Therapeutics (Cartesian Therapeutics) Business Description

Traded in Other Exchanges
Address
65 Grove Street, Watertown, MA, USA, 02472
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.
Executives
Carsten Brunn director, officer: President & CEO C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Peter G Traber officer: Chief Medical Officer 430 THAMER LANE, HOUSTON TX 77025
Takashi Kei Kishimoto officer: Chief Scientific Officer 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Lloyd P. Johnston officer: COO and SVP, R&D 480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Blaine Davis officer: Chief Financial Officer C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Carrie Smith Cox director SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Timothy C Barabe director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Timothy A Springer director 36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Kevin Tan officer: Chief Financial Officer 20 HICKORY ROAD, WELLESLEY MA 02482
Nishan M Desilva director 11119 NORTH TORREY PINES RD STE 200, LA JOLLA CA 92037
Ann K. Donohue officer: VP Finance C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, BUILDING ONE, WATERTOWN MA 02472
Bradford D. Dahms officer: Chief Financial Officer C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Goran Ando director
Scott Dunseth Myers director C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Elona Esq. Kogan officer: General Counsel C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065

Cartesian Therapeutics (Cartesian Therapeutics) Headlines